Drugs / Tovaxin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00587691 | Jul 2002 → Jun 2007 | relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis | Opexa Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00595920 | Nov 2007 → Dec 2008 | relapsing-remitting multiple sclerosis | Opexa Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00245622 | May 2006 → Sep 2008 | relapsing-remitting multiple sclerosis | Opexa Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tovaxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00245622 ↗ |
| Modality | Cell therapy | “The product consists of in vitro expanded myelin-reactive T-cells” PMID 22065170 ↗ Nov 2011 |
| Route | Subcutaneous | “subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24” NCT00245622 ↗ |